NCT05736939 is a clinical trial of Out-patient Pulmonary Rehabilitation in Post Acute COVID-19 Syndrome, sponsored by National and Kapodistrian University of Athens.

Who is sponsoring NCT05736939?

NCT05736939 is sponsored by National and Kapodistrian University of Athens.

What drugs are being tested in NCT05736939?

Interventions in NCT05736939: Out-patient Pulmonary Rehabilitation.

What condition does NCT05736939 study?

NCT05736939 studies Post Acute COVID-19 Syndrome.

Is NCT05736939 still recruiting?

NCT05736939 is currently completed. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT05736939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gender Differences in the Recovery Rate Following PR in Patients With Long COVID-19

Completed Last updated 11 October 2023

What this trial tests

trial testing Out-patient Pulmonary Rehabilitation in Post Acute COVID-19 Syndrome in 30 participants. Completed in 15 March 2023.

Timeline

1 October 2022

Primary endpoint
28 February 2023

15 March 2023

Quick facts

Lead sponsor	National and Kapodistrian University of Athens
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 October 2022
Primary completion	28 February 2023
Estimated completion	15 March 2023
Sites	1 location across Greece

Drugs / interventions tested

Out-patient Pulmonary Rehabilitation

Conditions studied

Post Acute COVID-19 Syndrome — all drugs for Post Acute COVID-19 Syndrome →

Sponsor

National and Kapodistrian University of Athens

Who can join

18 and older, any sex, with Post Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this retrospective analysis is to compare the magnitude of improvement in respiratory and peripheral muscle strength, following the completion of a hybrid pulmonary rehabilitation programme, in men and women with long COVID-19 syndrome. The main question it aims to answer is the following: • does gender limits the effects of a hybrid pulmonary rehabilitation programme on respiratory and peripheral muscle strength?

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exercise Intolerance Is Associated with Cardiovascular Dysfunction in Long COVID-19 Syndrome.
Vontetsianos A, Chynkiamis N, Gounaridi MI, Anagnostopoulou C, et al · · 2024 · cited 2× · PMID 39064183 · DOI 10.3390/jcm13144144
Rehabilitation in convalescent COVID-19 subjects improves right ventricular function.
Souvaliotis N, Vontetsianos A, Gounaridi MI, Chynkiamis N, et al · · 2025 · PMID 40458971 · DOI 10.5603/cj.103070
Rehabilitation-Induced Benefits Do Not Differ between Men and Women with Long Covid-19 Syndrome
Vontetsianos A, Chynkiamis N, Anagnostopoulou C, Lekka C, et al · · 2023 · DOI 10.2139/ssrn.4573769

Verify or expand the search:

Other National and Kapodistrian University of Athens trials

Trials by the same sponsor.

NCT07295964 — Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial · NA · not yet recruiting
NCT07351981 — TcPRF for Knee Osteoarthritis · NA · enrolling by invitation
NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
NCT07295899 — Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Impl · not yet recruiting
NCT06903130 — Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sN · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05736939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National and Kapodistrian University of Athens
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05736939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing